| [1] |
Ciccarelli FD, Acciarito A, Alberti S. Large and diverse numbers of human diseases with HIKE mutations[J]. Hum Mol Genet，2000，9(6)：1001-1007.
|
| [2] |
Ripani E, Sacchetti A, Corda D, et al. Human Trop-2 is a tumor-associated calcium signal transducer[J]. Int J Cancer，1998，76(5)：671-676.
|
| [3] |
Lipinski M, Parks DR, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies[J]. Proc Natl Acad Sci U S A，1981，78(8)：5147-5150.
|
| [4] |
Alberti S, Miotti S, Stella M, et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2[J]. Hybridoma，1992，11(5)：539-545.
|
| [5] |
Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth[J]. Oncogene，2013，32(2)：222-233.
|
| [6] |
Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications[J]. Genes Cancer，2015，6(3-4)：84-105.
|
| [7] |
Stoyanova T, Goldstein AS, Cai H, et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling[J]. Genes Dev，2012，26(20)：2271-2285.
|
| [8] |
Xu P, Zhao Y, Liu K, et al. Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas[J]. Cancer Manag Res，2017，9：821-837.
|
| [9] |
Zaman S, Jadid H, Denson AC, et al. Targeting Trop-2 in solid tumors: future prospects[J]. Onco Targets Ther，2019，12：1781-1790.
|
| [10] |
Zhang L, Yang G, Zhang R, et al. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells[J]. Int J Oncol，2018，53(2)：515-526.
|
| [11] |
陆莉. Trop-2基因在乳腺癌细胞侵袭中作用及机制探讨[D]. 江苏大学，2013.
|
| [12] |
Huang H, Groth J, Sossey-Alaoui K, et al. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors[J]. Clin Cancer Res，2005，11(12)：4357-4364.
|
| [13] |
Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy[J]. Int J Biol Macromol，2018，110：406-415.
|
| [14] |
Bardia A, Mayer I A, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer[J]. J Clin Oncol，2017，35(19)：2141-2148.
|
| [15] |
Mojica WD, Brandwein-Weber M, Korangy EA. A case of metastatic lobular carcinoma with overexpression of Trop-2: Implications for the consideration of novel therapeutics[J]. Breast J，2017，23(6)：757-759.
|
| [16] |
Vranic S, Palazzo J, Sanati S, et al. Potential novel therapy targets in neuroendocrine carcinomas of the breast[J]. Clin Breast Cancer，2019，19(2)：131-136.
|
| [17] |
Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer[J]. Oncol Rep，2018，40(2)：759-766.
|
| [18] |
陆莉，崔飞伦，肖秀娣，等. 乳腺癌组织中Trop-2蛋白的表达及意义[J]. 医学信息，2014(1)：98-99.
|
| [19] |
Oyama M, Nagashima T, Suzuki T, et al. Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer[J]. J Biol Chem，2011，286(1)：818-829.
|
| [20] |
Wu M, Liu L, Chan C. Identification of novel targets for breast cancer by exploring gene switches on a genome scale[J]. BMC Genomics，2011，12：547.
|
| [21] |
Guerra E, Trerotola M, Tripaldi R, et al. Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors[J]. Clin Cancer Res，2016，22(16)：4197-4205.
|
| [22] |
Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, Sacituzumab Govitecan, for the treatment of diverse metastatic solid tumors[J]. Clin Cancer Res，2015，21(17)：3870-3878.
|
| [23] |
Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)[J]. Oncotarget，2015，6(26)：22496-22512.
|
| [24] |
Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics[J]. Cancer，2017，123(19)：3843-3854.
|
| [25] |
Zangardi ML, Spring LM, Nagayama A, et al. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy？[J]. Expert Opin Investig Drugs，2019，28(2)：107-112.
|
| [26] |
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med，2019，380(8)：741-751.
|
| [27] |
Cardillo TM, Sharkey RM, Rossi DL, et al. Synthetic ethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer[J]. Clin Cancer Res，2017，23(13)：3405-3415.
|
| [28] |
Chang CH, Wang Y, Zalath M, et al. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers[J]. Mol Cancer Ther，2016，15(8)：1910-1919.
|
| [29] |
Liu D, Cardillo TM, Wang Y, et al. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer[J]. Mol Cancer，2014，13：53.
|
| [30] |
Strop P, Tran TT, Dorywalska M, et al. RN927C, site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models[J]. Mol Cancer Ther，2016，15(11)：2698-2708.
|
| [31] |
King GT, Eaton KD, Beagle BR, et al. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors[J]. Invest New Drugs，2018，36(5)：836-847.
|
| [32] |
Govindan SV, Stein R, Qu Z, et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel[J]. Breast Cancer Res Treat，2004，84(2)：173-182.
|
| [33] |
Sharkey RM, van Rij CM, Karacay H, et al. A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers[J]. J Nucl Med，2012，53(10)：1625-1632.
|
| [34] |
van Rij CM, Lutje S, Frielink C, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody[J]. Eur J Nucl Med Mol Imaging，2013，40(9)：1377-1383.
|
| [35] |
Saverio A．Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors：US，13/146012[P].2012-01-03.
|
| [36] |
Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo[J]. Int J Cancer，2014，134(5)：1239-1249.
|
| [37] |
Chang CH, Wang Y, Li R, et al. Combination herapy with ispecific ntibodies and PD-1 lockade nhances the ntitumor otency of T ells[J]. Cancer Res，2017，77(19)：5384-5394.
|